CB2R agonists have been shown to ameliorate albuminuria, reduce C-C motif Chemokine Receptor-2 (CCR2) expression in the renal cortex and cultured podocytes, lower mesangial expansion and decrease MCP1 expression in animal models of diabetes and obesity [257,259]. This evidence concerns the gene CCR2 and diabetes mellitus.